Dietary interventions for managing glucose abnormalities in cystic fibrosis: a systematic review protocol

Abstract

Glucose abnormalities are defined as follows: * Oral glucose tolerance test (OGTT): IGT: 120-min plasma glucose 7.8–11.1 mmol/l OR Glycated haemoglobin (HbA1c) ≥ 39 mmol/mol or ≥ 5.7%1 CFRD: fasting plasma glucose concentration ≥ 7.0 mmol/l OR 120-min plasma glucose ≥ 11.1 mmol/l OR HbA1c ≥ 48 mmol/mol or ≥ 6.5% [22] Continuous glucose monitoring (CGM) time above 7.8 mmol/l ≥ 4.5% [23]2 All studies in all CF patients will be included, but any additional medication that may affect glycaemia will be acknowledged and if of substantial effect, analysed separately. Outcomes Primary outcomes are: * Glycaemic control (OGTT, HbA1c; exploratory outcome: % of CGM time above 7.8 mmol/L) Secondary outcomes are: * Body weight (kg) * Height (m) * BMI (kg/m2)/ BMI-SDS (children & adolescents,) * Lung function (FEV1, FVC) * Mortality/adverse events * Adherence and acceptability of dietary intervention Study design A preliminary scoping search of the literature has identified limited evidence in this area. [...]all study design types will be included in this review (e.g. RCTs, prospective and retrospective cohort, cross-sectional, case control, case series). The following data will be extracted from each study: study design; sample characteristics (size, inclusion/exclusion criteria, sex, age, socioeconomic status); dietary intervention; results (including but not limited to glycaemic control, anthropometric measures, lung function, adherence and acceptability of dietary intervention); analysis methods; study limitations; and funding sources. Impaired glucose tolerance Declarations Funding This review is funded by the National Institute of Health Research (NIHR) as part of a Clinical Doctoral Research Fellowship (C-DRF) award held by the lead author (LB).